What is Retatrutide?
The complete guide to the triple-agonist peptide revolutionizing metabolic research.
Introduction
Retatrutide (LY3437943) is a novel, investigational peptide that acts as an agonist at three distinct receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. Because of this three-pronged approach, it is often referred to as a "triple G" or "tri-agonist."
Mechanism of Action
To understand why retatrutide is generating significant interest in the scientific community, it is essential to look at how each of its target receptors functions:
- GLP-1: Slows gastric emptying and signals satiety to the brain, reducing caloric intake.
- GIP: Enhances the insulin response to meals and improves fat tissue metabolic efficiency.
- Glucagon: Increases energy expenditure (basal metabolic rate) and promotes lipid mobilization (fat burning) in the liver.
By combining these three actions into a single molecule, retatrutide addresses obesity and metabolic dysfunction from multiple angles, leading to synergistic effects that outpace earlier generations of single or dual agonists.
Current Development Status
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) evaluating its efficacy and safety for obesity management, obstructive sleep apnea, and knee osteoarthritis. It has not yet been approved by the FDA, EMA, or MHRA for consumer use.